Q4 2025 · 13F-HR
Medicxi Ventures Management (Jersey) Ltdholdings as filed
Filed 2026-01-23 · accession 0001193125-26-020931
$835.0M
Reported value
5
Positions
2025-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $499.3M | 59.8% | 19,963,157 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $123.8M | 14.8% | 7,464,572 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $100.7M | 12.1% | 2,869,565 | Common | SOLE |
| 75382E109 | RAPT | RAPT THERAPEUTICS INC | $94.6M | 11.3% | 2,794,000 | Common | SOLE |
| 05153U107 | AURA | AURA BIOSCIENCES INC | $16.6M | 1.98% | 3,039,892 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.